Discovery of a potent melatonin-based inhibitor of quinone reductase-2 with neuroprotective and neurogenic properties

5-Methoxy-3-(5-methoxyindolin-2-yl)-1H-indole (3), whose structure was unambiguously elucidated by X-ray analysis, was identified as a multi-target compound with potential application in neurodegenerative diseases. It is a low nanomolar inhibitor of QR2 (IC50 = 7.7 nM), with greater potency than melatonin and comparable efficacy to the most potent QR2 inhibitors described to date. Molecular docking studies revealed the potential binding mode of 3 to QR2, which explains its superior potency compared to melatonin. Furthermore, compound 3 inhibits hMAO-A, hMAO-B and hLOX-5 in the low micromolar range and is an excellent ROS scavenger. In phenotypic assays, compound 3 showed neuroprotective activity in a cellular model of oxidative stress damage, it was non-toxic, and was able to activate neurogenesis from neural stem-cell niches of adult mice. These excellent biological properties, together with its both good in silico and in vitro drug-like profile, highlight compound 3 as a promising drug candidate for neurodegenerative diseases. [Display omitted] •5-Methoxy-3-(5-methoxyindolin-2-yl)-1H-indole (3): low-nanomolar QR2 inhibitor.•High selectivity towards QR2 compared with other melatonin receptors (MT1R, MT2R).•Compound 3: 5-LOX and MAOs inhibitor and potent radical-scavenger.•Neuroprotective properties vs. a cellular model of oxidative stress.•Neurogenic activity in vitro: potential help for the CNS auto-repair processes.